Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00225394 · ClinicalTrials.gov registry record
Long Term Use of Valganciclovir for Prophylaxis of CMV Disease in Kidney and Pancreas Transplant Patients
A clinical trial of Death and CMV Disease, sponsored by University of Massachusetts, Worcester.
- Completed
- Registry status
- 100
- Enrollment target
- 4
- Study locations
NCT00225394: Completed study of Death and CMV Disease, sponsored by University of Massachusetts, Worcester.
NCT00225394 is a study of Death and CMV Disease that has completed, run by University of Massachusetts, Worcester. The registered enrollment target is 100 participants, below the 26,854-participant average among 7 other Death trials with a reported enrollment target (100% lower). The trial reports 4 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00225394, a study of Death and CMV Disease, has completed, sponsored by University of Massachusetts, Worcester.
- COMPLETED
- Registry status
- 100 participants
- Enrollment target
- 4
- Study locations
Study Summary
CMV viral disease negatively affects transplant patients. CMV is the most prevalent infection in transplant patients and 3 month drug regimens to prevent the virus have been mostly unsuccessful, usually after the drug has been stopped, the patient develops the viral disease. Extended use of anti-viral drugs may, in fact, may lead to the development of resistant virus. We hypothesize that extended use (12 months) of valganciclovir (Valcyte™)will not only be efficacious but will not be associated with the development of resistant CMV. Sample Size: 100 patients at 3 sites have been enrolled Patient Selection: Adult (\>18 years) recipients of cadaveric or living donor kidneys, pancreas, or combine kidney-pancreas transplants. Immunosuppression: To be determined according to each center's standard protocol (s). Study Drug: Valcyte™ Days 0 - 90: All Patients, 900 mg QD Days 91 - 365: Group 1: 900 mg QD Group 2: 450 mg QD Assessment of Valgancicovir (Valcyte™)Resistant CMV : Serial serum samples (at transplant, 6 weeks, and 3, 6, 9 and 12 months post-transplant) for PCR amplification and DNA sequence analysis from detectable CMV to identify the presence of mutations within the UL97 and UL54 genes. Other Analyses: Additional information will be evaluated relating to the development of CMV disease, development of ganciclovir toxicity, graft rejection or graft loss and patient death. Preliminary information regarding the predictive value of DNA assays for the development of CMV disease will be evaluated.
Conditions Studied
Study Locations (4)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
- Lahey Clinic Transplant - Burlington
- UMass Memorial Medical Center - Worcester
Rhode Island
- Rhode Island Hospital - Providence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2003-10 |
| Est. Completion | 2006-07 |
What the finished NCT00225394 record still lists
NCT00225394 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 26,854-participant average among 7 other Death trials with a reported enrollment target (100% lower).
The record links to 4 conditions, with Death appearing as the primary indexed condition, and to 0 interventions.
NCT00225394 reports a single indexed study location in Massachusetts, Rhode Island.
Frequently Asked Questions
What is clinical trial NCT00225394 about?
NCT00225394 is a clinical study titled "Long Term Use of Valganciclovir for Prophylaxis of CMV Disease in Kidney and Pancreas Transplant Patients". CMV viral disease negatively affects transplant patients. CMV is the most prevalent infection in transplant patients and 3 month drug regimens to prevent the virus have been mostly unsuccessful, usually after the drug has been stopped, the patient develops the viral disease. Extended use of anti-vir...
What is the current status of trial NCT00225394?
This trial is currently completed. The enrollment target is 100 participants. The study started on 2003-10. Estimated completion is 2006-07.
What conditions does trial NCT00225394 study?
This clinical trial studies the following conditions: Death, CMV Disease, Viral Resistance, Rejection.
Who is sponsoring clinical trial NCT00225394?
This trial is sponsored by University of Massachusetts, Worcester, which has 240 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00225394 being conducted?
This trial has 4 study locations across Massachusetts, Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Death
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Diaphragmatic Initiated Ventilatory Assist (DIVA) Trial
RECRUITING · NA
-
Prostate Lung Colorectal and Ovarian (PLCO) Cancer Screening Trial
ACTIVE NOT RECRUITING
-
Health Insurance Instability and Mortality Among Patients Receiving Bup Tx for OUD
ACTIVE NOT RECRUITING
-
A Trial Evaluating Vitamin D Normalization on Major Adverse Cardiovascular-Related Events Among Myocardial Infarction Patients
COMPLETED · Phase 4
-
An Individualized Grief Intervention for Spouses of Cancer Patients After the Patient's Death
COMPLETED · NA
-
South Florida Residents Knowledge and Opinions on End-of-Life Issues
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia